Bleeding disorders and Agranulocytosis

Summary:

Agranulocytosis is found among people with Bleeding disorders, especially for people who are male, 60+ old.

The study analyzes which people have Agranulocytosis with Bleeding disorders. It is created by eHealthMe based on reports of 39 people who have Bleeding disorders from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Bleeding disorders?

Bleeding disorders is found to be associated with 1,197 drugs and 1,648 conditions by eHealthMe. Check the latest studies of Bleeding disorders.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,591 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 13, 2026

39 people who have Bleeding Disorders and Agranulocytosis are studied.

Would you have Agranulocytosis when you have Bleeding disorders?

Gender of people who have Bleeding Disorders and experienced Agranulocytosis *:

female: 45.95 %
male: 54.05 %

Age of people who have Bleeding Disorders and experienced Agranulocytosis *:

Common co-existing conditions for these people *:

Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 12 people, 30.77%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 11 people, 28.21%
Hypovitaminosis (any of several diseases caused by deficiency of one or more vitamins): 11 people, 28.21%
Dehydration (dryness resulting from the removal of water): 11 people, 28.21%
Nausea (feeling of having an urge to vomit): 10 people, 25.64%
High Blood Pressure: 10 people, 25.64%
Pain: 9 people, 23.08%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 20.51%
Iron Deficiency: 8 people, 20.51%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 7 people, 17.95%

Common drugs taken by these people *:

Common symptoms for these people *:

Thrombocytopenia (decrease of platelets in blood): 19 people, 48.72%
Anaemia (lack of blood): 15 people, 38.46%
Diarrhea: 10 people, 25.64%
Stomatitis (inflammation of mucous membrane of mouth): 8 people, 20.51%
Nosebleed (bleeding from nose): 8 people, 20.51%
Nausea (feeling of having an urge to vomit): 8 people, 20.51%
Hair Color Changes: 7 people, 17.95%
Oedema Peripheral (superficial swelling): 7 people, 17.95%
Mucosal Inflammation (infection of mucous membrane): 7 people, 17.95%
Malaise (a feeling of general discomfort or uneasiness): 7 people, 17.95%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

Related studies:

Treatments, associated drugs and conditions:

Bleeding disorders (24,450 reports)
Agranulocytosis (213,267 reports)

All the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

All the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,591 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Agranulocytosis and Bleeding disorders, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.